Tian An Medicare Limited Issues Profit Warning for FY2025

Key Highlights and Investor Implications

Tian An Medicare Limited (“the Company”, stock code: 383) has issued a profit warning for the financial year ended 31 December 2025. The announcement, made in compliance with the Hong Kong Listing Rules and the Securities and Futures Ordinance, is a significant update for shareholders and potential investors.

Financial Performance Overview

• Expected Loss: The Group anticipates recording a loss attributable to shareholders in the range of approximately HK\$15.0 million to HK\$45.0 million for FY2025. This represents a substantial reversal from the profit of HK\$28.8 million recorded in FY2024.
• Key Factors Behind the Loss:
  • Loss on fair value of investment properties
  • Provision for properties under development for sale
  • Provision for properties held for sale
  • Offsetting factors include a net foreign exchange gain (contrasted with a loss in 2024) and the absence of net loss related to the closure of the polyclinic, which impacted 2024 results
• Nature of Results: The results are preliminary and based on unaudited management accounts. They are subject to further adjustments, including impairment, fair value change, provision adjustments on properties, or other necessary adjustments.

Details and Important Information for Shareholders

• Significant Reversal in Performance: The swing from profit in 2024 to a material expected loss in 2025 is a crucial and price-sensitive development. The main drivers are losses related to property assets and provisions, which could indicate ongoing challenges in the Group’s property portfolio and may have a lingering effect on future performance.
• Potential Share Price Impact: Such a profit warning is typically viewed negatively by the market and could result in downward pressure on the share price. Shareholders and investors should be alert to the risk of further volatility.
• Uncertainty and Need for Caution: The results disclosed are unaudited and have not been reviewed by the auditors or the audit committee. The actual results, which are expected to be published in mid-March 2026, may differ from current estimates.
• Ongoing Review: The Company is finalising its annual results and advises shareholders to refer to the official results announcement for the most accurate financial position.

Corporate Governance Update

The Board comprises a mix of Executive Directors, Non-Executive Directors, and Independent Non-Executive Directors, with Mr. Kong Muk Yin serving as Executive Director and Mr. Lee Seng Hui as Chairman.

Action for Shareholders and Investors

• Exercise Caution: The Company explicitly advises shareholders and potential investors to exercise caution when dealing in the Company’s securities given the anticipated loss and the uncertainty until the audited figures are released.
• Stay Updated: Investors should closely monitor forthcoming announcements, particularly the official annual results release in March 2026, for any adjustments or further developments.

Disclaimer: This article is a summary and analysis based on the Company’s public announcement. The information is subject to change upon the release of audited results. Investors are urged to conduct their own due diligence and consult professional advisors before making any investment decisions. The author and publisher accept no liability for any losses arising from reliance on this information.

View TIANAN MEDICARE Historical chart here